Feature

Oramed oral insulin fails to meet goal in type 2 diabetes


 

Oramed Pharmaceuticals’ investigational oral insulin failed to achieve its primary endpoint in a phase 3 trial, according to top-line results announced by the company.

“Therefore, Oramed expects to discontinue its oral insulin clinical activities for [type 2 diabetes],” according to a company statement.

Top-line results were negative for the phase 3, randomized, double-blind, placebo-controlled, multicenter trial, ORA-D-013-1, comparing the efficacy of the insulin product ORMD-0801 to placebo in 710 people with type 2 diabetes with inadequate glycemic control on two or three oral glucose-lowering agents.

The participants were randomized 2:2:1:1 into ORMD-0801 dosed at 8 mg once or twice daily, or placebo dosed once or twice daily. They completed a 21-day screening period, followed by a 26-week double-blind treatment period.

The product didn’t achieve the primary endpoint comparing reduction in hemoglobin A1c from baseline to 26 weeks, or the secondary endpoint of mean change in fasting plasma glucose at 26 weeks. There were no serious adverse events.

Oramed Pharmaceuticals specializes in developing oral delivery formulations of drugs currently delivered via injection. The company has offices in the United States and Israel.

Oramed CEO Nadav Kidron commented in the statement, “Today’s outcome is very disappointing, given the positive results from prior trials. Once full data from the studies are available, we expect to share relevant learnings and future plans. We thank all the patients, families, and health care professionals who participated in the trial.”

Insulin manufacturer Novo Nordisk had also been developing an oral insulin product. Successful phase 2a results were presented at the American Diabetes Association’s 2017 Scientific Sessions and full phase 2 feasibility results were published in Lancet Diabetes & Endocrinology in 2019.

However, Novo Nordisk, which manufactures the oral glucagon-like peptide-1 receptor agonist semaglutide (Rybelsus), subsequently discontinued development of their oral insulin product. According to a statement, “Initial results raised questions about truly addressing patients’ unmet needs with insulin therapy. Therefore, we discontinued this work to focus on projects that could in fact improve cardiometabolic outcomes for people living with diabetes.”

A version of this article first appeared on Medscape.com.

Recommended Reading

DELIVER subanalysis ‘seals deal’ for dapagliflozin in HF
MDedge Cardiology
Intermittent fasting can lead to type 2 diabetes remission
MDedge Cardiology
Fitbit figures: More steps per day cut type 2 diabetes risk
MDedge Cardiology
Dubious diagnosis: Is there a better way to define ‘prediabetes’?
MDedge Cardiology
FDA approves Wegovy (semaglutide) for obesity in teens 12 and up
MDedge Cardiology
Diabetes surge expected in young people
MDedge Cardiology
Mediterranean diet linked with fewer pregnancy complications
MDedge Cardiology
Latest steps toward reducing U.S. insulin cost begin in 2023
MDedge Cardiology
PPI use in type 2 diabetes links with cardiovascular events
MDedge Cardiology
Fair access crucial for new diabetes/kidney disease drugs, say guidelines
MDedge Cardiology